The recent endorsement by the Food and Drug Administration (FDA) of ribociclib, marketed as Kisqali, marks a significant progression in the treatment of early high-risk breast cancer. Specifically approved for use in conjunction with endocrine therapy as an adjuvant treatment, this new indication broadens the therapeutic landscape for patients diagnosed with hormone receptor-positive and human
Health
Muscle-invasive bladder cancer (MIBC) presents a significant clinical challenge due to its high recurrence rate and bleak prognosis following standard treatments. Traditionally, neoadjuvant chemotherapy has aimed to improve overall survival rates by reducing tumor sizes before surgical intervention. A recent phase III trial, known as NIAGARA, marked a pivotal moment in this landscape by demonstrating
Recent advancements in the realm of oncology have highlighted the potential of combining retifanlimab (marketed as Zynyz) with standard chemotherapy to enhance treatment outcomes for patients suffering from locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC). Results from a phase III clinical trial have underscored the improved progression-free survival (PFS) associated
In recent years, there has been a growing interest in the relationship between hormone therapy (HT) and insulin resistance, particularly in healthy postmenopausal women. A systematic review and meta-analysis encompassing 23 randomized trials have shed light on this topic, indicating that hormone therapy may significantly reduce insulin resistance, a condition linked to various metabolic disorders.
Amid the ongoing political climate in the United States, the discourse surrounding healthcare continues to evoke strong reactions. Former President Donald Trump’s recent proposal to offer free in vitro fertilization (IVF) treatments has ignited a fierce debate among Republican factions. Many within the party are expressing discontent, arguing that such measures could conflict with traditional
A recent phase III trial examined the efficacy of mirtazapine, an inexpensive antidepressant, in alleviating severe, persisting breathlessness in patients with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). The primary outcome of the study was to evaluate the impact of mirtazapine on the “worst breathlessness” experienced by patients over the past 24
Alarming tales of presumed deceased organ donors waking up during the extraction process and silently pleading for help, organ transplant executives resorting to threats of being “cremated alive” against whistleblowers, and vital organs like pancreases being irresponsibly placed in freezers and then lost – this was the grim content present during the House Energy &
CAR T-cell therapy has emerged as a promising treatment option for patients with certain types of cancer, offering new hope for those who have exhausted standard-of-care options. However, recent concerns have been raised about the risk of developing second primary malignancies (SPMs) following CAR T-cell therapy. A systematic literature review and meta-analysis conducted by researchers
Childhood obesity is a significant public health concern, with long-term consequences for health and wellbeing. In recent years, there have been efforts to find effective treatments for obesity in young children. A recent phase IIIa trial, SCALE Kids, investigated the use of liraglutide in combination with lifestyle interventions to reduce BMI in children with obesity.
A recent analysis of two phase III trials has shed light on the potential benefits of perioperative nivolumab in reducing the risk of non-small cell lung cancer (NSCLC) recurrence or death. The studies compared patients who received perioperative nivolumab and chemotherapy post-surgery versus those who only received neoadjuvant nivolumab and chemotherapy. The results showed a